2025-11-17 02:42InnoCare Pharma (9969.HK) Earnings Review Summary Company Overview - Company: InnoCare Pharma (9969.HK) - Industry: Biotechnology Key Financial Highlights - 3Q Orela Sales: Rmb383 million, representing a 39% year-over-year (y/y) increase and 18% quarter-over-quarter (q/q) growth, compared to 4% q/q in 2Q25 [1] - Net Loss: Reduced to -Rmb34 million from -Rmb48 million in 2Q25, with slower growth in Selling, General and Administrative (SG&A) expenses at 19% y/y [1] - 2025 Guidance: Management raised orela sales growth guidance to 40% y/y from the previous 35% y/y [1] Growth Drivers - Hospital Coverage: Expansion in low-tier markets contributed to sales growth [1] - MZL Growth: Solid growth in MZL accounted for approximately 40% of new patient acquisitions [1] - Future Sales Momentum: Expected continued growth in orela sales in 2026E at 28% y/y, driven by newly reimbursed 1L CLL/SLL indication [1] New Product Development - Tafasitamab: Targeting the self-pay market with expected sales of Rmb100 million to Rmb200 million in 2026 [1] - Immunology Pipeline: Ongoing development with multiple catalysts: - ICP-332: Phase 3 data on AD expected by week 16 and phase 2 data for vitiligo in mid-2026 [3] - ICP-488: Phase 3 trial for psoriasis aiming for patient enrollment completion by year-end 2025 [3] - Orelabrutinib: Phase 2b data for SLE to be released in 4Q25 [3] Profitability Outlook - Profitability Expectations: Management anticipates turning profitable in 2025 post-Zenas deal, with core business profits expected by 2027 [2] - R&D Expenses: Projected at nearly Rmb1 billion for 2025, with a 15% y/y growth expected for 2026 [2] - Selling Expenses: Anticipated growth of 35%-40% y/y in 2026 to support the commercial launch of ITP indication in 2027 [2] Price Target and Risks - 12-Month Price Target: Revised to HK$24.54 for H-Share and Rmb47.28 for A-Share, reflecting an upside of 61.8% and 86.6% respectively [9][11] - Key Risks: Include R&D risks for clinical assets, uncertainties in pricing, potential entry of generic ibrutinib in 2027, and below-expected progress in global expansion [10] Conclusion - InnoCare Pharma shows strong sales growth and a promising pipeline, with management optimistic about future profitability and market expansion. The raised guidance and ongoing clinical trials position the company favorably within the biotechnology sector.